---
document_datetime: 2025-10-01 14:28:00
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/farydak-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: farydak-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.6705354
conversion_datetime: 2025-12-17 14:08:27.807631
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Farydak

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary         |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------|
| II/0030              | Submission of an updated RMP version 7.1 in order to align the RMP with GVP V and GVP XVII. As a consequence, the MAH proposes to remove severe haemorrhage and severe infections (including sepsis/pneumonia/reactivation of hepatitis B infection) as important identified risks, and | 28/11/2024                          |                                             | Annex II                         | Not applicable. |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | developmental toxicity, carcinogenicity/second primary malignancy (SPM), and medication error as important potential risks. In addition, the MAH proposes to revise the Annex II to reflect the removal of the Patient Card and educational programme as additional risk minimisation measures. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   |            |            |                        |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| PSUSA/10409 /202308 | Periodic Safety Update EU Single assessment - panobinostat                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 07/03/2024 | n/a        |                        | PRAC Recommendation - maintenance |
| IAIN/0028           | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 12/10/2023 | 04/11/2024 | SmPC, Labelling and PL |                                   |
| T/0027              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 01/03/2023 | 24/04/2023 | SmPC, Labelling and PL |                                   |
| PSUSA/10409 /202208 | Periodic Safety Update EU Single assessment - panobinostat                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 16/03/2023 | n/a        |                        | PRAC Recommendation - maintenance |
| IA/0025             | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 31/03/2022 | 08/07/2022 | SmPC                   |                                   |

<div style=\"page-break-after: always\"></div>

| PSUSA/10409 /202108   | Periodic Safety Update EU Single assessment - panobinostat                                                                                                                                                                             | 10/03/2022   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                          |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0023             | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 21/06/2021   | 08/07/2022 | Annex II and PL        |                                                                                                                                            |
| IA/0022               | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                       | 31/05/2021   | n/a        |                        |                                                                                                                                            |
| PSUSA/10409 /202008   | Periodic Safety Update EU Single assessment - panobinostat                                                                                                                                                                             | 11/03/2021   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                          |
| PSUSA/10409 /201908   | Periodic Safety Update EU Single assessment - panobinostat                                                                                                                                                                             | 26/03/2020   | 02/06/2020 | SmPC                   | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10409/201908. |
| R/0020                | Renewal of the marketing authorisation.                                                                                                                                                                                                | 27/02/2020   | 28/04/2020 | SmPC, Labelling and PL |                                                                                                                                            |
| T/0018                | Transfer of Marketing Authorisation                                                                                                                                                                                                    | 15/10/2019   | 04/11/2019 | SmPC, Labelling and PL |                                                                                                                                            |
| IA/0017/G             | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the                                                                                 | 19/08/2019   | n/a        |                        |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IG/1099             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 24/05/2019 | n/a |                                   |
| IB/0015             | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 03/05/2019 | n/a |                                   |
| PSUSA/10409 /201808 | Periodic Safety Update EU Single assessment - panobinostat                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 14/03/2019 | n/a | PRAC Recommendation - maintenance |
| II/0013             | Update of the RMP to version 5.0 in order to remove the commitment to conduct a non-interventional PASS study (LBH589D2408) of panobinostat use in relapsed or relapsed/refractory multiple myeloma patients who have received at least two prior regimens including bortezomib and an immunomodulatory agent in a real-world setting according to the current EU prescribing information and document adherence to dosing regimen (including the dosing card, blister pack) by describing clinical characteristics, frequency and severity of the medication error events; listed as a category 3 study in the RMP. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 14/02/2019 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| IA/0012             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                          | 18/06/2018   | 06/06/2019   | SmPC, Annex II, Labelling and PL   |                                                                                                                                            |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| T/0011              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                     | 20/03/2018   | 12/04/2018   | SmPC, Labelling and PL             |                                                                                                                                            |
| PSUSA/10409 /201708 | Periodic Safety Update EU Single assessment - panobinostat                                                                                                                                                                                                                                                                                                                                                                                              | 08/03/2018   | n/a          |                                    | PRAC Recommendation - maintenance                                                                                                          |
| IB/0009             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                           | 26/10/2017   | n/a          |                                    |                                                                                                                                            |
| PSUSA/10409 /201702 | Periodic Safety Update EU Single assessment - panobinostat                                                                                                                                                                                                                                                                                                                                                                                              | 28/09/2017   | n/a          |                                    | PRAC Recommendation - maintenance                                                                                                          |
| PSUSA/10409 /201608 | Periodic Safety Update EU Single assessment - panobinostat                                                                                                                                                                                                                                                                                                                                                                                              | 23/03/2017   | 23/06/2017   | SmPC                               | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10409/201608. |
| IB/0007/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch | 23/01/2017   | n/a          |                                    |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           | size B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other   |            |            |             |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| IB/0005/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 23/09/2016 | 16/02/2017 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| or supplier of the AS, starting intermediate used in the manufacturer of a novel B.I.b.2.c - Change in test starting material/reagent/intermediate changes to a test procedure does not have a significant quality of the AS B.I.d.1.z - Stability of period/storage period variation B.II.d.2.a - Change in product - Minor changes procedure B.II.f.1.b.1 - Stability life of the finished product (supported by real time B.III.1.b.2 - Submission deletion of Ph. Eur. TSE New certificate for a starting material/reagent/intermediate/or new or an already approved B.III.1.b.2 - Submission deletion of Ph. Eur. TSE New certificate for a starting material/reagent/intermediate/or new or an already approved B.III.1.b.2 - Submission deletion of Ph. Eur. TSE New certificate for a starting material/reagent/intermediate/or   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material) B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                         |            |     |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10409 /201602 | Periodic Safety Update EU Single assessment - panobinostat                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 02/09/2016 | n/a | PRAC Recommendation - maintenance |
| II/0002/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method | 21/04/2016 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|         | B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate   |            |            |                              |                                                                                                                                                                                                                                                                                                                                                  |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0003 | Update of section 4.6 of the SmPC in order to amend the safety information with a recommendation for pregnancy testing prior to treatment with Farydak, as a cautionary measure, in the Product Information. The Package Leaflet and the RMP (finally agreed version: 2.4) are updated in accordance. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                           | 25/02/2016 | 16/02/2017 | SmPC, Labelling and PL       |                                                                                                                                                                                                                                                                                                                                                  |
| II/0001 | Update of section 5.1 of the SmPC in order to update the safety information with regard to the key secondary endpoint of overall survival in the study D2308 to fulfil an Annex II condition (ANX 001). The Annex II of the product information is updated accordingly to remove the condition. As a                                                                                                                                                                                                                                                                                                              | 25/02/2016 | 16/02/2017 | SmPC, Annex II and Labelling | Section 5.1 of the SmPC has been updated to include the results from the final analysis of the Overall survival (OS) from the pivotal study CLBH589D2308. OS was the key secondary endpoint. OS was not statistically significantly different between the two treatment groups. The median OS was 40.3 months in the panobinostat + bortezomib + |

<div style=\"page-break-after: always\"></div>

| consequence the RMP ver.2.2 is provided. In addition, the Marketing authorisation holder (MAH) took the opportunity to correct an oversight in the Annex IIIA and add the Days and Weeks in section 5 under 'Other' in alignment with the approved blister foil mock-ups. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | dexamethasone arm and 35.8 bortezomib + dexamethasone (95% CI: 0.78, 1.14)).   | months in the placebo + arm (Hazard ratio: 0.94   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|---------------------------------------------------|